Abstract
Radiolabelled peptides and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation with clinical implications for several chronic inflammatory disorders for diagnosis, therapy decision making and follow up. In the last decades, a number of novel monoclonal antibodies and peptides have been introduced for the treatment of different inflammatory disorders and also labelled with a variety of radionuclides depending upon the specific applications, diagnostic or therapeutic, by using direct or indirect methods. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have an excellent diagnostic potential for the imaging of patients with chronic inflammatory diseases. In this review article we describe the characteristics of peptides, cytokines and monoclonal antibodies with a particular emphasis on their role in therapy decision making and follow up in different inflammatory diseases.
Keywords: Cytokines, monoclonal antibodies, radiopharmaceuticals, molecular imaging, inflammation, therapy decision making, diagnosis, nuclear medicine
Current Pharmaceutical Design
Title: Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Volume: 14 Issue: 24
Author(s): G. Malviya, A. Signore, B. Lagana and R. A. Dierckx
Affiliation:
Keywords: Cytokines, monoclonal antibodies, radiopharmaceuticals, molecular imaging, inflammation, therapy decision making, diagnosis, nuclear medicine
Abstract: Radiolabelled peptides and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation with clinical implications for several chronic inflammatory disorders for diagnosis, therapy decision making and follow up. In the last decades, a number of novel monoclonal antibodies and peptides have been introduced for the treatment of different inflammatory disorders and also labelled with a variety of radionuclides depending upon the specific applications, diagnostic or therapeutic, by using direct or indirect methods. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have an excellent diagnostic potential for the imaging of patients with chronic inflammatory diseases. In this review article we describe the characteristics of peptides, cytokines and monoclonal antibodies with a particular emphasis on their role in therapy decision making and follow up in different inflammatory diseases.
Export Options
About this article
Cite this article as:
Malviya G., Signore A., Lagana B. and Dierckx A. R., Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases, Current Pharmaceutical Design 2008; 14 (24) . https://dx.doi.org/10.2174/138161208785777414
DOI https://dx.doi.org/10.2174/138161208785777414 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway
Current Cancer Drug Targets New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review
Current Medicinal Chemistry Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology Serine Proteinase Inhibitors in the Skin: Role in Homeostasis and Disease
Current Protein & Peptide Science Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design Green Chemistry Approach as a Versatile Platform for Nanoparticles with Biomedical Applications
Nanoscience & Nanotechnology-Asia Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance
Current Enzyme Inhibition Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets The PI3 Kinase Signaling Pathway in Prostate Cancer
Current Cancer Drug Targets Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Gels and Jellies as a Dosage Form for Dysphagia Patients: A Review
Current Drug Therapy Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Recent Advance in Drug Development of Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design